BioCryst Pharmaceuticals and Idera Pharmaceuticals have terminated their merger agreement following the BioCryst stockholders’ failure to approve the adoption of the merger agreement at the BioCryst Special Meeting of Stockholders. “We respect and understand the views of our stockholders and are moving forward fully-focused on executing our business plan as a standalone company,” said Jon P.…